Related Experiment Video
Updated: Mar 8, 2026
Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
Published on: February 16, 2024
Novel insights into autoimmune gastritis: clinical profile and gastric neoplastic risk from an international
Marco Vincenzo Lenti1,2, Emanuela Miceli2, Irfan Soykan3
1Department of Internal Medicine and Medical Therapeutics, University of Pavia, Pavia, Italy a.disabatino@smatteo.pv.it marco.lenti@unipv.it.
Background:
International comparative data on autoimmune gastritis (AIG) remain limited.
Objective:
We aimed to describe AIG features and quantify the risk of gastric adenocarcinoma and type 1 gastric neuroendocrine tumours (NETs).
Design:
Retrospective study across eight tertiary centres in Europe, Türkiye, Latin America, the USA and Japan. Adults with histologically confirmed AIG were included. Clinical and follow-up data were collected to estimate adenocarcinoma and NET incidence and associated factors.
Results:
1240 patients were included (female:male 2:1; median age 59, IQR 48-67; median follow-up 68 months, IQR 36-108). Macrocytic anaemia predominated in Europe (45.6%), microcytic anaemia in Türkiye (56.1%) and Latin America (64.7%). Autoimmune comorbidities were most frequent in Latin America (67.7%). 36 (2.9%) gastric adenocarcinomas and 132 (10.6%) NETs occurred. No incident adenocarcinomas were reported in Latin America or Japan cohorts. Crude incidence rates ranged from 1.15 to 1.47 for adenocarcinoma and 0.70 to 1.62/100 person-years for NETs. Factors associated with adenocarcinoma included age >65 years (OR 4.50, 95% CI 2.18 to 9.27), intestinal metaplasia (OR 1.51, 95% CI 1.16 to 1.97), gastrin-17 >1316 pg/mL (OR 15.52, 95% CI 3.61 to 66.71) and prior proton pump inhibitor (PPI) (OR 5.74, 95% CI 2.13 to 15.47). For NETs, prior PPI (OR 2.69, 95% CI 1.12 to 6.46), smoking (OR 2.45, 95% CI 1.75 to 3.42), intestinal metaplasia (OR 2.88, 95% CI 1.38 to 6.01) and gastrin-17 >1316 pg/mL (OR 3.25, 95% CI 1.42 to 7.45), were associated with higher odds, while Helicobacter pylori eradication was associated with lower odds of NETs (OR 0.25, 95% CI 0.07 to 0.88).
Conclusion:
AIG presentation and neoplastic risks differ by region, warranting further research and potentially region-specific follow-up strategies.
Related Concept Videos
01:27Gastritis-I: Introduction and Types
Acute gastritis presents as a sudden inflammation triggered by various stressors to the stomach lining, such as exposure to corrosive agents, local irritants like aspirin and other NSAIDs, alcohol consumption, radiation therapy, physical trauma, severe burns, sepsis,...
01:17Gastritis-II: Pathophysiology
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
01:23Gastritis III: Clinical Manifestations and Management
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
01:21Barrett Esophagus-II: Clinical Manifestations and Management
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...